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Leveraging existing data to contextualize phase II clinical trial findings
in oncologyMore than 250 000 women are diagnosed with early-stage
breast cancer (EBC) in the USA each year.1 Of these, up to
30% have amplification of the human epidermal growth
factor 2 (HER2).2 The current standard of care for HER2-
positive (HER2þ) EBC is chemotherapy plus HER2-directed
therapy to complete 1 year of treatment.3 There is
growing interest in determining which patients with HER2þ
tumors could achieve favorable outcomes with less
chemotherapy through better HER2-targeting. The phase II
Adjuvant Paclitaxel and Trastuzumab (APT) trial by Tolaney
and colleagues4 provided compelling evidence that patients
with small HER2þ tumors without nodal macrometastases
can achieve highly favorable outcomes with paclitaxel and
trastuzumab alone (TH), avoiding the toxicity associated
with multi-agent chemotherapy regimens. Use of TH in this
context has been widely adopted in the clinical setting
despite the lack of a confirmatory phase III trial.
Phase II clinical trials have well-described limitations for
determining new standards of care, including lack of a
comparison arm or lack of sufficient power, even if
randomization is carried out, to enable firm conclusions
regarding relative efficacy. Phase III randomized trials,
though they provide stronger evidence regarding the
comparative efficacy of treatment alternatives, have prob-
lems of their own, including limited feasibility and afford-
ability in clinical contexts with favorable prognoses and low
event rates. Added to this is the larger size and design
complexity of noninferiority trials traditionally used to test
therapeutic minimalization. In small, node-negative, HER2þ
breast cancers, where recurrence rates with conventional
therapy are low, conducting a prospective, randomized trial
would require high patient accruals and long follow-up
times, resulting in a study that is prohibitively expensive
and takes many years to obtain results. Such study designs
in this clinical context do not adequately serve the needs of
the oncologic community and the patients whom we serve,
due to their inability to provide timely information to guide
patient care.
In a study published in this issue of Annals of Oncology,
Amiri-Kordestani and colleagues5 took a novel approach to
addressing the limitations of the phase II APT trial by using
pooled historical clinical trial data as an external control. In
doing so, they constructed a multi-agent chemotherapy arm
to which TH could be compared and selected patients with
similar demographic and clinical characteristics to those inthe experimental arm using propensity score matching to
address some of the problems with cross-trial comparisons.
In their analysis, the authors used existing patient-level data
from five clinical trials supporting drug approval by the US
Food and Drug Administration (FDA) for HER2þ EBC.6-9
They pooled data from these trials and selected patients
with low-risk EBC. Patients from the historical trials with
node-negative disease, tumors <3 cm (as required in the
APT trial), and treated with trastuzumab and either
anthracycline/cyclophosphamide/taxane (ACTH) or taxane/
carboplatin (TCH) were matched 1 : 1 to patients treated
with TH from the APT trial. To evaluate the impact of HER2-
directed therapy, they also matched and compared patients
treated with anthracycline/cyclophosphamide/taxane
without trastuzumab (ACT) to patients treated with TH.
They found similar invasive disease-free survival (iDFS) and
overall survival (OS) at 3 and 5 years between the ACTH/
TCH and TH arms. They also found improved iDFS and OS at
3 and 5 years when comparing TH with ACT.5
Cross-trial comparisons are fraught with limitations, in
part due to different study populations and lack of
randomization, introducing measured and unmeasured
confounders. In this case, the attempt to find comparable
patients for comparison across trials is particularly chal-
lenging because of inherent differences in the target pa-
tient populations for the ACTH and TCH registration trials
and the APT trial. The former set of trials deliberately
targeted higher risk patients, including those with node-
positive, estrogen receptor (ER)-negative, higher grade
disease and/or very young age, in order to obtain an event
rate sufficient to power a comparison between arms. In
contrast, the APT trial tested a de-escalation approach, and
thus appropriately limited its patient population to those
with relatively lower risk features, including tumors under
3 cm and those without nodal macrometastases, and was
conducted in an era where the core populations of the
earlier registration trials would have been largely treated in
a neoadjuvant fashion. The limited overlap of the trial
populations is illustrated by the fact that only 9% of the
registration trial patients were included in the external
control arm for this analysis, and 96 of 401 APT patients
could not be matched to a comparator patient from the
registration trial pool. Nevertheless, the authors in this
study made appropriate efforts to address measurable
confounders through propensity score matching according
to age (in years), tumor size (in granular increments of Tmi/
T1a, T1b, T1c, and T2), ER status, progesterone receptor
status, and histologic grade.5 The subsets selected for
comparison appear to be substantively similar on 
measured prognostic features, with the exception of 
slightly more grade 3 tumors (62.3% versus 58.7%) among 
TCH/ACTH patients compared with TH patients. While they 
could not eliminate the possibility of selection bias due to 
unmeasured confounders, their reasonable and thoughtful 
approach to homogenize the study groups addresses these 
concerns as best as can be done outside of a prospective, 
randomized trial, and sets a hopeful precedent for future 
use of external control arms, where randomized compari-
sons are infeasible.
Another limitation of cross-trial comparisons, as the 
study authors point out, is time-trend bias, which could not 
be easily adjusted for using statistical methods. The histor-
ical clinical trials used for comparison in this study enrolled 
the bulk of patients between 2000 and 2005,6-9 while the 
APT trial was conducted between 2007 and 2010.4 While 
improvements in treatment delivery and supportive care 
that may impact survival should always be considered, it is 
unlikely that there was substantial variation in clinical care 
during such a short gap in time.
Acknowledging that evaluation of phase II study findings 
with a prospective, randomized, controlled trial is ideal but 
not always feasible, is there any other way to contextualize 
phase II findings? Another data source that could be lever-
aged for comparisondthough also fraught with limi-
tationsdis electronic health record (EHR)-derived patient-
level data. While single-institution databases lack the 
numbers needed for comparison, and claims databases lack 
the granular clinical information required to construct a well-
matched comparison group, novel datasets such as the 
American Society of Clinical Oncology’s CancerLinQ database 
that integrate patient-level data from multiple health sys-
tems may one day provide the volume of patients and the 
richness of clinical data to enable such comparisons.10 The 
FDA has identified advancing real-world data into regulatory-
quality real-world evidence as a key strategic priority.11 In its 
present state, due in large part to the limitations of the EHRs 
from which it is sourced, CancerLinQ and other pooled EHR 
databases generally lack sufficient completeness of clinical 
information, such as tumor size, nodal status, histologic 
grade, and receptor status, necessary to enable matched 
comparisons of real-world and study data. Perhaps even 
more importantly, aggregated EHR data rarely capture can-
cer recurrence and progression events, a key end point of 
clinical trials, in a complete, accurate, and structured 
manner. Additionally, the more diverse populations treated 
in clinical practice, while improving the generalizability of the 
comparator pool, may also prove challenging to match to 
highly selected clinical trial participants, predictably resulting 
in discordance between real-world and trial outcomes.12 
Improving the data quality of aggregate real-world data-
bases requires improving the quality of structured data el-
ements documented in the EHR, as well as additional tools 
such as natural language processing and human cura-
tion.10,13 These challenges are not insurmountable, but will 
take time and innovation to reduce reliance on clinician data 
entry, which is inherently variable and resource intensive,and increase automation, linkage, and curation processes to
improve data quality and enhance the interoperability of
data across different health systems and records. The Mini-
mal Common Oncology Data Elements (mCODE) initiative
reflects these efforts to leverage real-world data for research
purposes. This initiative aims to provide a common standard
and language for oncology to standardize and collect data in
a computable manner so it can be aggregated and analyzed
with data from many other patients, exchanged through
interoperable EHR systems, collected in a streamlined
manner without burdening clinicians, and protect patient
privacy. The rigor of data collection required in the trial
setting, and the manpower required to support it, is not the
standard in clinical practice, but data collection in clinical
practice can evolve to be better adapted to provide real-
world evidence, leveraging the power of the EHR and data
mining tools.
In the meantime, Amiri-Kordestani and colleagues5 pro-
vide an innovative approach for using historical clinical trial
data to contextualize phase II study findings in HER2þ EBC
that can be easily applied to other contexts. Their study
provides reassuring findings that patient outcomes with TH
are similar to those achieved with ACTH or TCH in this
patient population with low clinical risk, and therefore de-
escalation of therapy for patients with small, node-
negative HER2þ breast cancers is appropriate. Their
approach is particularly well-suited for studies looking at de-
escalation therapies. In breast oncology, a similar approach
could be applied to the results of ongoing studies evaluating
the impact of HER2-directed therapy, without or with
limited chemotherapy, in patients with HER2þ EBC.14,15 The
FDA’s Oncology Center of Excellence has longstanding in-
terest in streamlining drug approvals through use of syn-
thetic control arms based on data from prior clinical trials to
evaluate the efficacy of new drugs or serve as a comparator
arm for prospective clinical trials in rare tumor types.11,16
Doing so can improve accrual to clinical trials and in-
crease patient access to promising new therapies. This study
by Amiri-Kordestani and colleagues, notably led by FDA
investigators, provides a promising example of the FDA’s
commitment to leveraging existing data to advance scien-
tific progress.
Historically, large randomized clinical trials have been the
flagships of treatment advancement in oncology. However,
those who argue that prospective, randomized trials are the
only standard by which to practice clinical medicine will, in
many cases, find themselves waiting for a trial that will never
materialize, or one that takes so long that it is completed after
the standards of care have evolved, making the hypothesis
less relevant or difficult to interpret. Comparative studies,
such as the one by Amiri-Kordestani and colleagues, are not
intended to replace phase III trials. However, in the context of
clinical conditions with favorable outcomes and low event
rates, study designs that utilize existing comparator data to
replace prospectively collected control arms may be more
affordable, nimble, and timely, and, when understood for
what they are rather than what they are not, serve as a
valuable contribution to the body of evidence in clinical
oncology. The authors here demonstrate how, with a 
thoughtful study design, we can use existing data to advance 
scientific knowledge in a timely and affordable manner to 
answer clinically-relevant questions in oncology.E. M. Ray*, L. A. Carey & K. E. Reeder-Hayes
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